Angiotensin Converting Enzyme Inhibitors and Periprocedural Myocardial Infarction
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Metabolic syndrome (MS) has been reported as a risk for cardiovascular events. The aim of the present cohort study is to investigate whether ACEi therapy reduces the rate of periprocedural myocardial injury (PPMI) after elective percutaneous coronary intervention (PCI) among patients with metabolic syndrome.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Metabolic syndorme (MS) was defined as the presence of 3 or more of these components:
high fasting glucose (fasting serum glucose ≥100 mg/dl or drug treatment for elevated blood glucose)
abdominal obesity (given as waist circumference >102 cm in men and >88 cm in women)
high blood pressure (>130/>85 mmHg or drug treatment for hypertension)